CAI · NASDAQ
Caris Life Sciences (CAI) Stock Price & Fundamentals
Caris Life Sciences (CAI) closed at $221.53 on Oct 9, 2026, down 1.11% from the previous close of $224.02.
Share price, past year
1Y +19.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $221.53 |
| Sep 30, 2026 | $222.25 |
| Aug 31, 2026 | $209.28 |
| Jul 31, 2026 | $210.74 |
| Jun 30, 2026 | $203.27 |
| May 29, 2026 | $186.07 |
| Apr 30, 2026 | $192.16 |
| Mar 31, 2026 | $188.37 |
| Feb 27, 2026 | $178.05 |
| Jan 30, 2026 | $189.43 |
| Dec 31, 2025 | $193.99 |
| Nov 28, 2025 | $179.55 |
| Oct 31, 2025 | $187.72 |
Key statistics
- Market cap
- $62.60B
- P/E (TTM)
- 26.6
- EPS (TTM)
- $8.32
- Revenue (TTM)
- $989.61M
- Net income (TTM)
- $105.14M
- Shares outstanding
- 282.6M
- Dividend yield
- —
- 52-week range
- $175.90 – $226.36
Caris Life Sciences's market cap is $62.60B, based on a share price of $221.53 and 282.6M shares outstanding as of Jun 30, 2026.
Financials
Caris Life Sciences reported revenue of $812.03M for fiscal 2025, up 96.97% from fiscal 2024.
Caris Life Sciences reported a net loss of $68.09M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $812.03M | +97.0% | −$68.09M | −8.4% | −$3.22 | $66.90M |
| FY2024ended Dec 31, 2024 | $412.26M | +34.7% | −$281.89M | −68.4% | −$10.66 | −$253.64M |
| FY2023ended Dec 31, 2023 | $306.13M | — | −$341.42M | −111.5% | −$13.24 | −$298.42M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $263.71M | −$637.00K | $0.00 |
| Q1 FY2026ended Mar 31, 2026 | $216.17M | −$510.00K | $0.00 |
| Q4 FY2025ended Dec 31, 2025 | $292.89M | $81.96M | $8.24 |
| Q3 FY2025ended Sep 30, 2025 | $216.83M | $24.33M | $0.08 |
| Q2 FY2025ended Jun 30, 2025 | $181.40M | −$71.79M | −$7.97 |
| Q1 FY2025ended Mar 31, 2025 | $120.92M | −$102.58M | −$3.57 |
| Q3 FY2024ended Sep 30, 2024 | $101.62M | −$67.73M | −$2.59 |
| Q2 FY2024ended Jun 30, 2024 | $100.05M | −$66.19M | −$2.54 |
Company profile
- Name
- Caris Life Sciences, Inc.
- Ticker
- CAI
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Medical Laboratories
- Headquarters
- 750 W John Carpenter Freeway, Suite 800, Irving, TX 75039
- Incorporated in
- TX
- Fiscal year ends
- December
- SEC CIK
- 0002019410
Recent SEC filings
- Sep 14, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jun 5, 2026
- May 8, 2026
- May 7, 2026
- Apr 2, 2026
- Mar 3, 2026
Frequently asked questions
What is Caris Life Sciences's stock price?
Caris Life Sciences (CAI) closed at $221.53 on Oct 9, 2026, down 1.11% from the previous close of $224.02.
What is Caris Life Sciences's market cap?
Caris Life Sciences's market cap is $62.60B, based on a share price of $221.53 and 282.6M shares outstanding as of Jun 30, 2026.
How much revenue does Caris Life Sciences make?
Caris Life Sciences reported revenue of $812.03M for fiscal 2025, up 96.97% from fiscal 2024.
What is CAI's P/E ratio?
Caris Life Sciences's price-to-earnings ratio is 26.6, based on trailing twelve-month diluted EPS of $8.32.
Does Caris Life Sciences pay a dividend?
Caris Life Sciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Caris Life Sciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures